Key facts
- This page summarizes Ansbert Gadicke's Form 4 filing for Allovir, Inc. (KLRS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Aug 2022, 16:34.
Ansbert Gadicke - 28 Jul 2022 Form 4 Insider Report for Allovir, Inc. (KLRS)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- KLRS
- Reported as of
- 28 Jul 2022
- Net transaction value
- +$15,000,000
- SEC form
- 4
- Accepted by SEC
- 01 Aug 2022, 16:34:52 UTC
- Prior SEC filing
- 23 Jun 2022
- Next SEC filing
- 24 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brett Hagen, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ansbert Gadicke filed Form 4 for Allovir, Inc. (KLRS) on 01 Aug 2022.
Change
- Previous filing in this sequence was filed on 23 Jun 2022.
- Current net transaction value: +$15,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALVR
transaction
Common Stock
Award
- Transaction value
- $15,000,000
- Shares
- +3,253,796
- Change %
- +24%
- Price
- $4.61
- Shares after
- 16,674,766
- Date
- 28 Jul 2022
- Ownership
- By ElevateBio LLC
- Footnotes
- F1, F2
ALVR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 30,197
- Date
- 28 Jul 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.
Footnote F2
Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.